A potential and new drug for stroke, another one.

Nature Reviews Drug Discovery Volume 8 | March 2009 | 183

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted in favour of approving prasugrel, an oral anticoagulant developed by Daiichi Sankyo and Eli Lilly.

The advisory committee, however, agreed that the benefit of preventing myocardial infarction, cardiovascular death and stroke outweighs the risk of major bleeding, such as haemorrhages, and voted 9–0 in favour of prasugrel approval.